what are glp 1 receptor agonists GLP-1 Potential Use of GLP-1 and

Most Common Adverse Events Key Observations: Gastrointestinal adverse events are dose-dependent and most pronounced during dose escalation Symptoms typically peak within the first 4-8 weeks and diminish with continued treatment as tolerance develops Slow titration (4-week intervals) significantly reduces the incidence and severity of GI events Most adverse events classified as mild to moderate in severity [9] Discontinuation Rates 7.3% Placebo discontinuation rate [9] 15.8% Cagrilintide 2.4 mg (optimal dose) [9] 24.5% Cagrilintide 4.5 mg (high dose) [9] The majority of discontinuations due to adverse events occurred during the titration phase, with GI symptoms (nausea, vomiting) being the primary reasons

doi:10.1016/j.neubiorev.2015.04.015 Jay R

Furthermore, downstream IRE1 signaling components have also been shown to be of interest to drug discovery programs (Marciniak et al

Monitoring progress and adjusting protocols Starting a peptide protocol is not a set-and-forget situation